Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

Since the FDA announced that tirzepatide is (for now) out of shortage, APC’s Scott Brunner has been all over the news offering our perspective. Here’s just a sampling:

Axios: “FDA warns compounding pharmacies on weight-loss drugs“

Fierce Pharma: “Eli Lilly’s shortage of diabetes and obesity drugs is over, halting competition with knock-offs“

The New York Times: “Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says“

The Washington Post: “Eli Lilly’s weight-loss drug no longer in shortage, FDA says“